Human umbilical cord mesenchymal stem cell therapy (Tianjin Angsai Cell Gene Engineering)

人脐带间充质干细胞（天津昂赛细胞基因工程）

Report date: 2025/12/03 17:07:54

Base Information

Drug NameHuman umbilical cord mesenchymal stem cell therapy (Tianjin Angsai Cell Gene Engineering)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokeGraft vs Host DiseaseKidney Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTianjin Angsai Cell Gene Engineering Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHong Kong Advanced Regenerative Medical Technology Co LtdTianjin Angsai Cell Gene Engineering Co Ltd
Inactive CompaniesN/A
Active IndicationsIschemic StrokeGraft vs Host DiseaseKidney Diseases +[6] 
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksN/A